Daily Judi: Friday, February 24, 2023
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Insilico Medicine's new COVID-19 therapeutic, named ISM3312, will begin clinical trials in China. The drug was designed in its entirety by generative AI. (Toronto Star)
Jessica Hamzelou reports on the recent Fifth International Brain Stimulation Conference in Lisbon, Portugal—where neuroscientists, surgeons, ethicists, and psychiatrists meet to discuss new stimulation therapies for brain disorders. (MIT Technology Review)
Gilead features Stacey Bledsoe, Head of Clinical Trial Diversity and Inclusion, and tells the story of how her father’s illness demonstrated the need for equity in clinical trials.
Our Culture
“We work proactively with each client, analyzing our reports to make them work faster, to help make our client’s life better.”
–Tim, Trial Delivery
About Judi
Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 171 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 certified collaboration platform.